N-Substituted Indole Derivatives as Dual EP2/EP4 Antagonists
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for various diseases, including cancers and inflammatory conditions, often face limitations due to the overexpression of EP2 and EP4 receptors, which can lead to immune suppression and tumor growth, and existing COX-2 inhibitors have cardiovascular side effects.
Innovation Solution
Development of novel N-substituted indole derivatives that act as dual antagonists of the EP2 and EP4 receptors, potentially offering a safer alternative for treating cancers and inflammatory conditions by modulating prostaglandin signaling pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If COX-2 inhibitors are used to treat cancers and inflammatory conditions, then tumor growth and inflammation are suppressed, but cardiovascular side effects occur
Solution Approach 1:
The invention segments the prostaglandin signaling pathway by developing selective EP2 and EP4 receptor antagonists that specifically block these receptors without inhibiting COX-2 enzyme activity. This segmentation allows targeted suppression of tumor growth and inflammation while avoiding the cardiovascular side effects associated with broad COX-2 inhibition, as the drug does not interfere with prostacyclin synthesis which is crucial for cardiovascular health
Solution Approach 2:
The patent introduces a new class of compounds that act as intermediaries by selectively binding to EP2 and EP4 receptors and blocking PGE2 signaling. These compounds serve as a mediator between the harmful PGE2 overactivation and the desired therapeutic outcome, achieving cancer and inflammation treatment without triggering the cardiovascular adverse effects that occur with direct COX-2 enzyme inhibition
2Reliability
If EP2 and EP4 receptors are overexpressed, then immune suppression and tumor growth are promoted, but blocking these receptors with existing drugs causes cardiovascular issues
Solution Approach 1:
The invention applies local quality by creating compounds with high selectivity for EP2 and EP4 receptors specifically in tumor and inflammatory tissues. The dual antagonist compounds exhibit preferential binding to these overexpressed receptors in the pathological microenvironment while maintaining minimal affinity for other prostaglandin receptors in cardiovascular tissues, thereby achieving localized therapeutic action without systemic cardiovascular toxicity
Solution Approach 2:
The patent utilizes parameter changes by optimizing the chemical structure of indole derivatives to achieve specific binding characteristics. By modifying molecular parameters such as substituent groups on the indole core, the compounds achieve enhanced selectivity for EP2/EP4 receptors with dissociation constants in the nanomolar range, allowing potent antagonism of tumor-promoting PGE2 signaling while sparing cardiovascular prostaglandin pathways
Data Source
AI summary
The present invention relates to derivatives of formula (I)wherein (R1)n, R2, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.